ZEPHYRTEL
2.4.2019 11:51:04 CEST | Business Wire | Press release
ZephyrTel, a division of ESW Capital dedicated to serving global telecommunications operators, is pleased to announce that it has today signed a telecom-focused Strategic Collaboration Agreement with Amazon Web Services (AWS).
This agreement comes less than a year after ZephyrTel’s formation and is testament to the company’s growth strategy and focus on cloud leadership in the Telco market. The strategic collaboration agreement will initially be focused on a joint go-to market approach based on ZephyrTel’s industry leading Customer Experience Management platform, ResponseTek for Telco, which was the first ZephyrTel solution to be migrated to AWS.
Work is already underway to migrate other ZephyrTel solutions to AWS, including Mobilogy, OASIS Cloud Contact Centre, Volt Delta 360 Directory Assistance, PeerApp and Vasona, as well as NewNet Messaging and the Invigorate Rating and Charging platform which ZephyrTel acquired in December 2018.
ZephyrTel’s Dev Factory is also working with AWS in the Artificial Intelligence (AI) and Machine Learning (ML) space and development is underway on the first suite of predictive analytics applications built on AWS.
Mike Shinya, CEO of ZephyrTel, said, “We are dedicated to partnering with our 330 global Telco Operator customers on their journey to becoming Digital Telcos. We expect our cloud offerings to deliver Total Cost of Ownership savings to our customers of up to 90% and we are thrilled to work with AWS’s dedicated Telecom business to extend our joint offerings.”
“Telecommunication service providers are accelerating their migration to AWS in order to deliver lower total cost of IT for their organizations as well as increase automation of their services and business processes in order to drive agility and innovation for their customers,” said Jean-Philippe Poirault, Vice President and Global Head of Telecom, Amazon Web Services EMEA SARL. “We are excited to support ZephyrTel in delivering cloud-deployable telecom solutions on AWS to enable and accelerate the digital transformation journey of our shared customers.”
The agreement will also see ZephyrTel join the AWS Partner Network (APN) with immediate effect. The APN is a global partner program that helps APN Partners build successful AWS-based businesses or solutions by providing business, technical, marketing, and go-to-market support.
About ZephyrTel
Launched in early 2018, ZephyrTel has rapidly scaled up to reach $70M revenues in a short space of time. ZephyrTel has installations in over 50 countries around the world and its customers include more than 330 of the global leading Telecom Operators. The company has access to over 4000 of the world’s top talented engineers and other skilled professionals, available through affiliated company Crossover for Work’s platform. ZephyrTel is currently serving the telecommunications industry worldwide with software products for retail, infrastructure, mobile, cloud, and customer experience and is continuously extending its telco product range. More information is available at www.zephyrtel.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005511/en/
Contact:
ZephyrTel For further information please email: Mike Shinya, CEO mike.shinya@zephyrtel.com Ali Perkins, Chief Marketing Officer ali.perkins@zephyrtel.com
For media enquiries please email: Paula Elliott, Managing Director, C8 Consulting paula@c8consulting.co.uk
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom